GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acceleron Pharma Inc (NAS:XLRN) » Definitions » Shiller PE Ratio

Acceleron Pharma (Acceleron Pharma) Shiller PE Ratio : (As of Apr. 26, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Acceleron Pharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Acceleron Pharma Shiller PE Ratio Historical Data

The historical data trend for Acceleron Pharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acceleron Pharma Shiller PE Ratio Chart

Acceleron Pharma Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Acceleron Pharma Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Acceleron Pharma's Shiller PE Ratio

For the Biotechnology subindustry, Acceleron Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acceleron Pharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acceleron Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Acceleron Pharma's Shiller PE Ratio falls into.



Acceleron Pharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Acceleron Pharma's E10 for the quarter that ended in Sep. 2021 is calculated as:

For example, Acceleron Pharma's adjusted earnings per share data for the three months ended in Sep. 2021 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2021 (Change)*Current CPI (Sep. 2021)
=-1.16/115.7343*115.7343
=-1.160

Current CPI (Sep. 2021) = 115.7343.

Acceleron Pharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201112 0.820 95.213 0.997
201203 -0.684 96.783 -0.818
201206 -0.678 96.819 -0.810
201209 -0.666 97.633 -0.789
201212 -0.818 96.871 -0.977
201303 -0.112 98.209 -0.132
201306 0.027 98.518 0.032
201309 -5.620 98.790 -6.584
201312 -0.640 98.326 -0.753
201403 -0.300 99.695 -0.348
201406 -0.520 100.560 -0.598
201409 -0.250 100.428 -0.288
201412 -0.550 99.070 -0.643
201503 -0.450 99.621 -0.523
201506 -0.320 100.684 -0.368
201509 -0.360 100.392 -0.415
201512 -0.810 99.792 -0.939
201603 0.130 100.470 0.150
201606 -0.590 101.688 -0.671
201609 -0.550 101.861 -0.625
201612 -0.510 101.863 -0.579
201703 -0.660 102.862 -0.743
201706 -0.770 103.349 -0.862
201709 -0.650 104.136 -0.722
201712 -0.620 104.011 -0.690
201803 -0.580 105.290 -0.638
201806 -0.630 106.317 -0.686
201809 -0.630 106.507 -0.685
201812 -0.750 105.998 -0.819
201903 -0.740 107.251 -0.799
201906 -0.340 108.070 -0.364
201909 -0.860 108.329 -0.919
201912 -0.440 108.420 -0.470
202003 -0.950 108.902 -1.010
202006 -0.340 108.767 -0.362
202009 -0.660 109.815 -0.696
202012 -0.950 109.897 -1.000
202103 -1.050 111.754 -1.087
202106 -1.050 114.631 -1.060
202109 -1.160 115.734 -1.160

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Acceleron Pharma  (NAS:XLRN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Acceleron Pharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Acceleron Pharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Acceleron Pharma (Acceleron Pharma) Business Description

Traded in Other Exchanges
N/A
Address
128 Sidney Street, Cambridge, MA, USA, 02139
Acceleron Pharma is a biotechnology company focused on the discovery, development, and commercialization of novel therapies. The company's research focuses on key natural regulators of cellular growth and repair. Acceleron generates its revenue through collaboration, licensing, and research arrangements with collaboration partners for the development and commercialization of therapeutic candidates. The company sometimes uses contract research organizations and research institutions outside the United States.
Executives
Sujay Kango officer: EVP, Chief Commercial Officer 1028 CHAMBERS COURT, BRIDGEWATER NJ 08807
Kevin F Mclaughlin officer: SVP, CFO and Treasurer C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Adam M Veness officer: SVP, General Counsel and Sec. C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Thomas A Mccourt director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Karen L. Smith director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Joseph S Zakrzewski director 509 WATERVIEW PLACE, NEW HOPE PA 18938
Habib J Dable director, officer: CEO and President C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Terrence C Kearney director IN CARE OF HOSPIRA, INC., 275 NORTH FIELD DRIVE, LAKE FOREST IL 60045
Laura Hamill director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Bristol Myers Squibb Co 10 percent owner 430 E. 29TH STREET 14 FLOOR NEW YORK NY 10016
Celgene Corp /de/ 10 percent owner 86 MORRIS AVENUE, SUMMIT NJ 07901
Christopher Hite director C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Francois Nader director 550 HILLS DRIVE, BEDMINSTER NJ 07921
Jean George director CRITICAL THERAPEUTICS INC, 60 WESTVIEW STREET, LEXINGTON MA 02421
Kemal Malik director C/O ACCELERON PHARMA INC. 128 SIDNEY STREET CAMBRIDGE MA 02139

Acceleron Pharma (Acceleron Pharma) Headlines

From GuruFocus

Acceleron Announces Third Quarter 2021 REBLOZYL� Net Sales

By Business Wire Business Wire 10-27-2021